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Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous
peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is
signiﬁcantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to
patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60
(hazard ratio [HR], 1.71; 95% conﬁdence interval [CI], 1.12 to 2.62; P ¼ .013) and transplantation for multiple
myeloma (HR, 2.80; 95% CI, 1.60 to 4.90; P ¼ .0003) were associated with an increased risk of this compli-
cation. When stratiﬁed for myeloma patients only, age > 60 (HR, 1.80; 95% CI, 1.13 to 2.87; P ¼ .013) and prior
treatment with both lenalidomide and bortezomib (HR, 1.83; 95% CI, 1.11 to 3.04; P ¼ .0001) were associated
with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemo-
mobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this
complication (HR, 3.05; 95% CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation
exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide signiﬁ-
cantly affects the subsequent risk of developing ES.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION for MM, non-Hodgkin lymphoma, or Hodgkin lymphoma
Autologous peripheral blood stem cell transplantation
(PBSCT) remains a cornerstone of the therapeutic arma-
mentarium for patients with multiple myeloma (MM) and
lymphoma [1,2]. Treatment-related mortality and morbidity
after autologous PBSCT are typically low because of
rapid reconstitution of immunity and hematopoietic func-
tion [3]. Some patients, however, develop an engraftment
syndrome (ES), commonly characterized by fever, skin rash,
and diarrhea and, less frequently, by hepatic dysfunction,
transient encephalopathy, and a capillary leak syndrome
[4-7]. Although the syndrome is mild and self-limited in
most patients, a subset can develop serious complications
[8,9], often characterized by inﬂammation in the gastroin-
testinal tract [10-13], which can be fatal [12,14,15]. Recent
evidence indicates that this complication is increasing in
recipients of autologous PBSCT [4,16], although the precise
explanation for this increased incidence and why it may be
higher in patients with MM [12] has remained elusive. In
this study, we reviewed 591 consecutive autologous PBSCTsedgments on page 1372.
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13.06.017between 2001 and 2010 to deﬁne risk factors for the
development of ES.MATERIAL AND METHODS
Patients
The clinical records of 591 consecutive autologous PBSCTs for treatment
of MM, non-Hodgkin lymphoma, or Hodgkin lymphoma at the Medical
College of Wisconsin between 2001 and 2010 were reviewed to determine
the incidence of ES. The patient demographics, disease characteristics, stem
cell mobilization therapy, and treatments administered to patients before
and at the time of transplantation are shown in Table 1. The PBSC mobili-
zation method was evaluable in all 591 transplantations. Patients were
mobilized by ﬁlgrastim (16 mcg/kg) alone in 26% (n ¼ 155); ﬁlgrastim and
plerixafor (.24 mg/kg) in 5% (n ¼ 27); ﬁlgrastim (10 mcg/kg) and chemo-
therapy in 65% (n ¼ 386); ﬁlgrastim (16 mcg/kg) and sargramostim
(granulocyte-macrophage colony stimulating factor) (500 mcg/m2) in 3%
(n ¼ 15); and ﬁlgrastim, chemotherapy, and plerixafor in 1% (n ¼ 8). All
patients received postgrafting treatment with either ﬁlgrastim (n ¼ 560,
95%) or pegylated ﬁlgrastim (n ¼ 31, 5%) to accelerate myeloid engraftment.
Patients were maintained on antimicrobial prophylaxis with ﬂuconazole
and acyclovir. Ciproﬂoxacin was begun prophylactically when patients
became neutropenic. Patients were diagnosed with ES using minor modi-
ﬁcations of previously published criteria [7,8]. Speciﬁcally, patients were
deemed to have ES when presenting with a noninfectious fever and 1 other
symptom (ie, diarrhea, skin rash, pulmonary inﬁltrates, and hepatic
dysfunction), or a combination of rash, diarrhea, and pulmonary inﬁltrates
during the peri-engraftment period, which was deﬁned as up to 3 days prior
and 10 days after the day of engraftment. A noninfectious fever was deﬁned
as a temperature > 100.4F (38C) without microbiological culture positive
infection and no documented response to antibiotic administration. Diar-
rhea was considered 2 or more episodes of liquid defecations per dayTransplantation.
Table 1
Patient and Treatment Characteristics of Patients with and without ES
ES No ES P Value
Number of transplantations 131 460
Age at transplantation, median (range), yr 61 (26 to 77) 56 (18 to 79) .002
18 to 50 22 (17) 135 (29)
50 to 60 33 (25) 156 (34)
60 to 70 61 (47) 125 (27)
70 to 80 15 (11) 44 (10)
Gender .36
Male 75 (57) 285 (62)
Female 56 (43) 175 (38)
Year of transplantation <.001
2001 to 2005 19 (15) 150 (33)
2006 to 2010 112 (85) 310 (67)
Multiple myeloma 114 (87) 307 (67) <.001
Non-Hodgkin lymphoma 14 (11) 102 (22) .003
Hodgkin lymphoma 3 (2) 51 (11) .001
Conditioning regimen* <.001
BEAM 11 (8) 147 (32)
Melphalan alone 114 (87) 304 (66)
Others 6 (5) 9 (2)
Outpatient transplantations 9 (7) 24 (5) .52
Disease status before transplantationy <.001
CR 30 (23) 130 (28)
PR 77 (59) 171 (37)
SD 4 (3) 16 (3)
Prog/rel 15 (11) 121 (27)
Missing 5 (4) 22 (5)
Lines of therapy before PBSCT .70
1 54 (41) 198 (43)
2 40 (31) 159 (35)
>2 37 (28) 103 (22)
Growth factor support after transplantationz
Filgrastim 123 (94) 431 (95) .65
Pegylated ﬁlgrastim 8 (6) 23 (5) .66
No. CD34þ cells  106/kg, median (range) 5.0 (2 to 30) 4.0 (2 to 34) .05
Myeloma pre-PBSCT chemotherapyx
Lenalidomide-based 52 (40) 75 (16) <.001
Bortezomib-based 79 (60) 145 (32) <.001
Thalidomide-based 28 (21) 90 (20) .71
Lenalidomide þ bortezomib 41 (30) 55 (12) <.001
Cytotoxic chemotherapy 29 (25) 106 (35) .06
Cyclophosphamide exposure (chemotherapy and/or mobilization) 62 (51) 237 (78) <.001
Mobilization method
Cytokine-basedjj 69 (53) 129 (28) <.001
Chemotherapy-based{ 63 (47) 341 (72) <.001
Time from transplantation to discharge, median (range), d 17 (13 to 157) 15 (7 to 42) <.001
Time to ANC > 500 x 109/L, median (range), d 12 (10 to 29) 12 (7 to 40) .52
Time to plts > 20 x 109/L, median (range), d 22 (7 to 82) 21 (7 to 395) .15
Data are presented as n (%) unless otherwise indicated.
ES indicates engraftment syndrome; CR, complete remission; PR, partial remission; SD, stable disease; Prog/Rel, progressive disease/relapse; ANC, absolute
neutrophil count; plts, platelets.
* Conditioning regimens: Mel (melphalan 200 mg/m2); BEAM (carmustine 300 mg/m2, cytarabine 400 mg/m2, etoposide 200 mg/m2, melphalan 140 mg/m2),
Others (ES): Cyclophosphamide þ TBI (n ¼ 2), TBI þ Etoposide (n ¼ 1), unspeciﬁed (n ¼ 3); (No ES): Cyclophosphamide þ TBI (n ¼ 1), Busulfan þ Cyclo-
phosphamide (n ¼ 1), Cyclophosphamide þ Cisplatin (n ¼ 1), Cyclophosphamide þ TBI þ Etoposide (n ¼ 3), TBI (n ¼ 1), unspeciﬁed (n ¼ 2).
y Disease status before ASCT was deﬁned according to the international working group criteria for MM and lymphoma [28,29].
z Growth factor support post-transplantation was with either ﬁlgrastim at a dose of 5 mcg/kg beginning day þ5 or pegylated ﬁlgrastim at a dose of 6 mg
starting on day þ1.
x Total of numbers in parentheses for each cohort exceed 100% because some patients received therapeutic regimens that contained multiple agents.
jj Cytokine-based mobilization consisted of regimens that employed the following agents: ﬁlgrastim (16 mcg/kg), plerixafor (.24 mg/kg), and sargramostim
(500 mcg/m2).
{ Chemotherapy-based mobilization was with cyclophosphamide plus ﬁlgrastim, or cyclophosphamide plus ﬁlgrastim and plerixafor.
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papular exanthema covering > 25% of the body surface area and not due
to a drug reaction or underlying infection. Pulmonary inﬁltrates were
conﬁrmed by chest x-ray or computed tomography scans of the chest and
not secondary to infectious or cardiopulmonary etiologies. Transient
encephalopathy was deﬁned as confusion not secondary to any other
etiology. Hepatic dysfunction was deﬁned as a total bilirubin  2 mg/dL or
transaminase levels  2 times the upper limit of normal. The day of
neutrophil engraftment was denoted as the ﬁrst of 3 consecutive days with
an absolute neutrophil count > 0.5 x 109/L. This retrospective cohort study
was approved by the institutional review board of the Medical College of
Wisconsin.Statistical Analysis
Patient-related factors were compared between patients with and
without ES using the Wilcoxon rank-sum test for continuous variables and
the chi-square test for categorical variables. Forty-three patients received
a second autologous PBSCT, and 1 patient underwent 3 transplantations.
Therefore, a total of 591 observations occurred from 547 patients to identify
risk factors associated with developing ES. A random effect logistical
regression model was used to adjust for repeated measures. The variables
considered in the regression model building were age, gender, diagnosis,
pretransplantation mobilization method, pretransplantation disease status,
pretransplantation induction chemotherapy, including novel agents, cyclo-
phosphamide and other cytotoxic chemotherapy, posttransplantation
Table 2
Clinical Features of Patients with ES



















ES indicates engraftment syndrome.
Data are presented as n (%) unless otherwise indicated.
* Weight gain, renal insufﬁciency and/or transient encephalopathy.
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elimination model selection procedure was employed to identify statisti-
cally signiﬁcant covariates to be added into the model [17]. A statistical
signiﬁcance (alpha) level of .05 was used throughout. All computations were
made using the statistical package SAS version 9.2 (SAS Institute, Cary, NC).RESULTS
Of the 591 transplantations from 2001 to 2010, ES
developed in 131 (22%) cases at a median of 12 days (range, 6
to 37) after transplantation. There was no difference in the
incidence of ES in patients who underwent their ﬁrst trans-
plantation (22%, 119 of 547) versus those who received
a second transplantation (28%,12 of 43) (P¼ .78). Themedian
time of ES diagnosis was 1 day after neutrophil engraftment.
Fever (90%), diarrhea (68%), and rash (50%) were the most
common manifestations, whereas liver function test abnor-
malities, noncardiogenic pulmonary inﬁltrates, weight gain,
renal insufﬁciency, and transient encephalopathy were all
observed in a minority of patients (Table 2). Signiﬁcant
factors for development of ES included patient age > 60 (P <
.01); year of transplantation (2006 to 2010) (P < .001);
diagnosis of multiple myeloma (P < .001); treatment withTable 3
Risk Factors for ES by Multivariate Analysis
n HR 95% CI P value
Characteristics (entire cohort)
Age
18 to 59 245 1.00 e .013
60 to 79 346 1.71 1.12 to 2.62
Disease
NHL and HL 170 1.00 e .0003
Multiple myeloma 421 2.80 1.60 to 4.90
Multiple myeloma only
Age
18 to 59 212 1.00 e .013
60 to 79 209 1.80 1.13 to 2.87
Myeloma treatment with both lenalidomide and bortezomib
No 325 1.00 e .0001*
Yes 96 1.83 1.11 to 3.04
Cyclophosphamide exposure (chemotherapy and/or mobilization)
Yes 299 1.00 e <.0001
No 122 3.05 1.91 to 4.87
ES indicates engraftment syndrome; CI, conﬁdence interval; NHL, non-
Hodgkin lymphoma; HL, Hodgkin lymphoma; HR, hazard ratio.
* Overall 2 degrees of freedom.lenalidomide, bortezomib, or a combination of lenalidomide
and bortezomib (P < .001 for all combinations); lack of
exposure to cyclophosphamide (P < .001 for induction
chemotherapy or chemomobilization); use of melphalan
conditioning (P < .001); and disease status of complete
remission or partial remission before transplantation (P <
.001) (Table 1). ES was signiﬁcantly more common after
2005, in the era of novel antimyeloma agents used in
induction (P < .001). Patients with ES had longer hospital
stays with a median admission of 17 days (range, 12 to 157)
versus 15 days (range, 7 to 58) in those without this
complication (P < .001). There was no difference in the time
to neutrophil or platelet engraftment between the 2 groups.
By multivariate analysis, myeloma (HR, 2.80; P ¼ .0003),
and age  60 years (HR, 1.71; P ¼ .013) were associated with
a signiﬁcantly higher risk of developing ES (Table 3). When
stratiﬁed for MM patients only, pretransplantation exposure
to both lenalidomide and bortezomib (HR, 1.83; P ¼ .0001)
and age  60 (HR, 1.80; P ¼ .013) were strongly associated
with the development of ES. Conversely, a lack of pre-
transplantation exposure to cyclophosphamide (HR, 3.05;
P< .0001) was also signiﬁcantly associated with an increased
risk of ES. The majority of patients who were exposed to
cyclophosphamide received it as part of mobilization therapy
as opposed to pretransplantation-induction chemotherapy
(81% versus 19%, respectively). There were 6 patient deaths
directly attributable to ES or immunosuppression required
for treatment of this complication. MM was the underlying
malignancy in all cases of patient death. There was no
difference in transplantation-related mortality, relapse,
progression-free survival, or overall survival between
patients with and without ES for the entire patient cohort
and for those patients withmultiplemyeloma only (Figures 1
and 2). The median follow-up time for the entire patient
cohort was 49 months.
DISCUSSION
This study demonstrates that patients with MM are at
highest risk for the development of ES and that exposure to
novel immunomodulatory agents is a major risk factor for
this potentially life-threatening complication. Although
exposure to these agents has been speculated to be a risk
factor for the more severe manifestations associated with ES
[11,12], this study for the ﬁrst time establishes a direct
association between ES and novel agents. We believe that
these results have clinical signiﬁcance, given that these
agents are increasingly being used in combination in the
initial induction treatment of patients who are destined to
undergo autologous PBSCT [18]. Moreover, this is a potential
explanation for the increased frequency of this syndrome
that has been noted in prior publications [4,16].
The precise mechanism by which patients develop
this complication remains incompletely understood,
although release of proinﬂammatory cytokines early after
transplantation as a consequence of conditioning regimen-
induced tissue damage is thought to play a pathophysiolog-
ical role [8]. We believe that an additional component of the
pathophysiology of ES is attributable to the loss of self-
tolerance, which can lead to the emergence of autoimmune
manifestations, particularly within the colon microenviron-
ment. The gastrointestinal tract, in particular, is sensitive to
the loss of tolerance, which is likely a reﬂection of the
increased antigen load in these tissues due to the presence of
commensal organisms that can serve as additional immune
targets [19,20]. Notably, this has been the site of most severe
Figure 1. Transplantation outcomes in all patients with and without ES. Cumulative incidence of transplantation-related mortality (TRM) and relapse are depicted in
panels A and B. Probability of progression-free survival and overall survival are shown in panels C and D.
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been observed in the majority of patients who ultimately
died from this complication. It is noteworthy that we did not
observe an increased risk in patients who received prior
therapy with thalidomide, but we did note an increased risk
in patients with prior exposure to lenalidomide (Table 1).
This suggests that newer immune modulating agents may
have more profound effects on regulatory networks within
the immune system and subsequent immune reconstitution.
In that regard, studies have shown that both lenalidomide
and pomalidomide can inhibit both the proliferation and
function of regulatory T cells in humans and inmurine tumorFigure 2. Transplantation outcomes in multiple myeloma patients with and without E
are depicted in panels A and B. Probability of progression-free survival and overall sumodels, whereas thalidomide did not have any effect [21].
Furthermore, this would be an explanation for why prior
studies including patients who did not receive novel
immunomodulatory agents as pretransplantation therapy
and who developed autologous graft-versus-host disease in
the gastrointestinal tract reported much less overall
morbidity [10].
Our results also indicate that pretransplantation exposure
to cyclophosphamide, as either a component of induction
therapy or administered to facilitate stem cell mobilization,
protects against the development of ES. This may explain
why the incidence of ES was much less in patients with non-S. Cumulative incidence of transplantation-related mortality (TRM) and relapse
rvival are shown in panels C and D.
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the most common chemotherapeutic regimens (ie, R-CHOP
(rituxan-cyclophosphamide, adriamycin, vincristine, and
prednisone), R-EPOCH (rituxan-etoposide, prednisone,
vincristine, cyclophosphamide, and adriamycin)) used to
treat these patients during induction or relapse. Notably,
a similar association has been observed in smaller cohorts of
patients with polyneuropathy, organomegaly, endocrinop-
athy, M-protein, and skin abnormalities (POEMS) syndrome,
where themajority of cases of ES occurred in those recipients
who were not exposed to cyclophosphamide before trans-
plantation [9,22]. In the current report, we have now
extended this observation to a much larger and broader
group that encompasses all MM patients.
Cyclophosphamide has been employed in both preclinical
rodent models and clinical trials in humans to deplete
regulatory T cells to enhance antitumor immunity [23-25].
Therefore, one might presume that cyclophosphamide
would enhance autoimmune manifestations in patients
exposed to this agent. However, studies by Condomines et al.
[26] demonstrated that the combination of granulocyte
colony-stimulating factor and cyclophosphamide adminis-
tered as mobilization therapy resulted in an increased
frequency of regulatory T cells in the stem cell product in
patients undergoing autologous HSCT for multiple myeloma.
Furthermore, these cells were shown to be functional in
in vitro suppression assays. The retention of competent
regulatory T cells within autologous stem cell products after
cyclophosphamide-based mobilization therapy would,
therefore, be an explanation for the reduced incidence of ES
in this MM patient cohort. The association of prior cyclo-
phosphamide exposure and a reduced incidence of ES also
has potential signiﬁcance in the selection of an induction
regimen for initial therapy. A wide array of regimens has
been examined in the treatment of myeloma patients
constituting doublet, triplet, and even quadruplet combina-
tions of active agents [18]. With respect to cyclophospha-
mide, it is noteworthy that a triplet regimen containing this
drug has been shown to be equivalent to one containing
novel agents alone [27]. Thus, when considering possible
induction regimens that appear to yield equivalent results,
the selection of a cyclophosphamide-based combinationmay
help to obviate the development of this complication and
reduce subsequent morbidity after autologous PBSCT, if
growth factor alone is employed for stem cell mobilization.
In summary, these studies demonstrate that the
pretransplantation treatment of myeloma patients with
novel immunomodulatory agents increases the risk of ES,
whereas prior cyclophosphamide exposure is protective for
development of this complication. Additionally, these
data raise the caution that use of newer, more potent
immunomodulatory agents in the treatment of plasma cell
dyscrasias, coupled with the increasing use of cytokine-
based mobilization approaches, may result in an unin-
tended increase in this syndrome, particularly in older
individuals who are most susceptible to this complication.
Clinicians should therefore be cognizant of this possibility as
they care for these patients.ACKNOWLEDGMENTS
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